492 related articles for article (PubMed ID: 16828495)
1. Excess soluble urokinase-type plasminogen activator receptor in the plasma of dialysis patients correlates with increased fibrinolytic activity.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 119(4):475-80. PubMed ID: 16828495
[TBL] [Abstract][Full Text] [Related]
2. Oxidative stress effects fibrinolytic system in dialysis uraemic patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2006; 117(5):517-22. PubMed ID: 15964061
[TBL] [Abstract][Full Text] [Related]
3. The urokinase-type plasminogen activator/its soluble receptor system is independently related to carotid atherosclerosis and associated with CC-chemokines in uraemic patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2008; 122(3):328-35. PubMed ID: 18048089
[TBL] [Abstract][Full Text] [Related]
4. Effects of long-term erythropoietin therapy on fibrinolytic system in haemodialyzed patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2008; 121(6):787-91. PubMed ID: 17869326
[TBL] [Abstract][Full Text] [Related]
5. Urokinase-type plasminogen activator and metalloproteinase-2 are independently related to the carotid atherosclerosis in haemodialysis patients.
Pawlak K; Pawlak D; Myśliwiec M
Thromb Res; 2008; 121(4):543-8. PubMed ID: 17706748
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of plasma urokinase-type plasminogen activator and urokinase-type plasminogen-activator receptor in patients with acute and chronic hepatitis B.
Zhou H; Wu X; Lu X; Chen G; Ye X; Huang J
Thromb Res; 2009; 123(3):537-42. PubMed ID: 18691743
[TBL] [Abstract][Full Text] [Related]
7. Urokinase-type plasminogen activator, receptor, and inhibitor correlating with gelatinase-B (MMP-9) contribute to inflammation in gouty arthritis of the knee.
Chu SC; Yang SF; Lue KH; Hsieh YS; Hsiao TY; Lu KH
J Rheumatol; 2006 Feb; 33(2):311-7. PubMed ID: 16465663
[TBL] [Abstract][Full Text] [Related]
8. The level of urokinase-type plasminogen activator receptor is increased in serum of ovarian cancer patients.
Sier CF; Stephens R; Bizik J; Mariani A; Bassan M; Pedersen N; Frigerio L; Ferrari A; Danø K; Brünner N; Blasi F
Cancer Res; 1998 May; 58(9):1843-9. PubMed ID: 9581823
[TBL] [Abstract][Full Text] [Related]
9. Blood urokinase plasminogen activator system in chronic urticaria.
Kasperska-Zajac A; Brzoza Z; Rogala B
Arch Dermatol Res; 2007 Jan; 298(8):409-11. PubMed ID: 17102952
[TBL] [Abstract][Full Text] [Related]
10. Vascular endothelial growth factor and uPA/suPAR system in early and advanced chronic kidney disease patients: a new link between angiogenesis and hyperfibrinolysis?
Pawlak K; Ulazka B; Mysliwiec M; Pawlak D
Transl Res; 2012 Nov; 160(5):346-54. PubMed ID: 22683425
[TBL] [Abstract][Full Text] [Related]
11. Significantly increased concentration of soluble urokinase-type plasminogen activator receptor in the blood of patients with pelvic inflammatory disease.
Yeh YH; Wang PH; Lin LY; Tee YT; Chou MC; Yang SF; Tsai HT
Clin Chim Acta; 2013 Jan; 415():138-44. PubMed ID: 23117033
[TBL] [Abstract][Full Text] [Related]
12. The plasma level of soluble urokinase receptor is elevated in patients with Streptococcus pneumoniae bacteraemia and predicts mortality.
Wittenhagen P; Kronborg G; Weis N; Nielsen H; Obel N; Pedersen SS; Eugen-Olsen J
Clin Microbiol Infect; 2004 May; 10(5):409-15. PubMed ID: 15113317
[TBL] [Abstract][Full Text] [Related]
13. Soluble urokinase plasminogen activator receptor in preoperatively obtained plasma from patients with gynecological cancer or benign gynecological diseases.
Riisbro R; Stephens RW; Brünner N; Christensen IJ; Nielsen HJ; Heilmann L; von Tempelhoff GF
Gynecol Oncol; 2001 Sep; 82(3):523-31. PubMed ID: 11520150
[TBL] [Abstract][Full Text] [Related]
14. Haemostatic system, biochemical profiles, kynurenines and the prevalence of cardiovascular disease in peritoneally dialyzed patients.
Pawlak K; Mysliwiec M; Pawlak D
Thromb Res; 2010 Feb; 125(2):e40-5. PubMed ID: 19732942
[TBL] [Abstract][Full Text] [Related]
15. Tissue factor and urokinase-type plasminogen activator system are related to the presence of cardiovascular disease in hemodialysis patients.
Pawlak K; Pawlak D; Mysliwiec M
Thromb Res; 2007; 120(6):871-6. PubMed ID: 17331567
[TBL] [Abstract][Full Text] [Related]
16. [The plasma levels of urokinase plasminogen activator and urokinase plasminogen activator receptor and plasminogen activator inhibitor-1 in patients with different stages of liver cirrhosis following chronic hepatitis B].
Wu XR; Wang Q; Shi SS; Lu MH; Guo WD
Zhonghua Gan Zang Bing Za Zhi; 2004 Feb; 12(2):82-4. PubMed ID: 14980106
[TBL] [Abstract][Full Text] [Related]
17. Hyperfibrinolysis, uPA/suPAR system, kynurenines, and the prevalence of cardiovascular disease in patients with chronic renal failure on conservative treatment.
Pawlak K; Buraczewska-Buczko A; Mysliwiec M; Pawlak D
Am J Med Sci; 2010 Jan; 339(1):5-9. PubMed ID: 19926968
[TBL] [Abstract][Full Text] [Related]
18. Prognostic significance of soluble urokinase plasminogen activator receptor in serum and cytosol of tumor tissue from patients with primary breast cancer.
Riisbro R; Christensen IJ; Piironen T; Greenall M; Larsen B; Stephens RW; Han C; Høyer-Hansen G; Smith K; Brünner N; Harris AL
Clin Cancer Res; 2002 May; 8(5):1132-41. PubMed ID: 12006529
[TBL] [Abstract][Full Text] [Related]
19. Reduced release of intact and cleaved urokinase receptor in stimulated whole-blood cultures from human immunodeficiency virus-1-infected patients.
Ostrowski SR; Piironen T; Høyer-Hansen G; Gerstoft J; Pedersen BK; Ullum H
Scand J Immunol; 2005 Apr; 61(4):347-56. PubMed ID: 15853918
[TBL] [Abstract][Full Text] [Related]
20. The prognostic value of plasma soluble urokinase plasminogen activator receptor (suPAR) levels in stage III ovarian cancer patients.
Begum FD; Høgdall CK; Kjaer SK; Christensen L; Blaakaer J; Bock JE; Glud E; Høyer-Hansen G; Ring-Larsen H; Høgdall EV
Anticancer Res; 2004; 24(3b):1981-5. PubMed ID: 15274388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
